trending Market Intelligence /marketintelligence/en/news-insights/trending/agu3zi3ymfmhlgysbclr0q2 content esgSubNav
In This List

Cronos Group, Ginkgo Bioworks tie up on cannabinoid production


According to Market Intelligence, December 2022


Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes


Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook


Japan M&A By the Numbers: Q3 2022

Cronos Group, Ginkgo Bioworks tie up on cannabinoid production

Cronos Group Inc. and Ginkgo Bioworks Inc. are collaborating to produce cultured cannabinoids.

Under the exclusive partnership, Ginkgo, a Boston-based biotechnology company, will work with Cronos on the research and development of microorganisms capable of producing certain target cannabinoids.

Cronos will fund certain R&D and foundry expenses expected to be about US$22 million, subject to the achievement of certain milestones.

Upon Ginkgo's demonstration that the microorganisms are capable of producing the target cannabinoids above a minimum productivity level, Cronos will issue up to about 14.7 million common shares.

Assuming all milestones are met, the transaction's value would total US$100 million.

Cronos will have the exclusive right to use and commercialize the key patented intellectual property related producing the target cannabinoids globally.

Cronos, a Toronto-based cannabis company, intends to produce and distribute the target cannabinoids globally and has received confirmation that this method of production is permitted under the Cannabis Act of Canada.